Evidence map›Paper›PMID 38754577›Full record

ArticleNeuropharmacology2024

Assessment of the antinociceptive, respiratory-depressant, and reinforcing effects of the low pK

Shelley R Edwards, Bruce E Blough, Kristian Cowart, Grace H Howell, Aaron A Araujo, Jacob P Haskell, Sally L Huskinson, James K Rowlett, Marcus F Brackeen, Kevin B Freeman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shelley R EdwardsDepartment of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA; School of Medicine, University of Mississippi Medical Center, Jackson, MS, 39216, USA. Electronic address: Sredwards@umc.edu.
Bruce E BloughRTI International, Research Triangle Park, NC, 27709, USA.
Kristian CowartUtrecht University, Heidelberglaan 8, 3548, CS, Utrecht, the Netherlands.
Grace H HowellSchool of Medicine, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
Aaron A AraujoDepartment of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
Jacob P HaskellProgram in Neuroscience, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
Sally L HuskinsonDepartment of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA; Center for Innovation and Discovery in Addiction, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
James K RowlettDepartment of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA; Center for Innovation and Discovery in Addiction, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
Marcus F BrackeenRTI International, Research Triangle Park, NC, 27709, USA.
Kevin B FreemanDepartment of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA; Center for Innovation and Discovery in Addiction, University of Mississippi Medical Center, Jackson, MS, 39216, USA.

Funding

ANXIOLYTIC EFFECTS AND ABUSE OF BZ RECEPTOR LIGANDSR01DA011792 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI ROWLETT, JAMES K · 1998 to 2024
$7.8M
Deterrents for prescription opioid abuseR01DA039167 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI FREEMAN, KEVIN B. · 2015 to 2025
$4.9M
Tolerance and Physical Dependence after Chronic Benzodiazepine TreatmentR01DA043204 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI JAMES K ROWLETT · 2017 to 2026
$4.3M
Behavioral Pharmacology of Injury Restricted Fentanyl Analogues.F30DA057093 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI EDWARDS, SHELLEY R · 2022 to 2024
$62k
NIDA NIH HHS F30 DA057093NIDA NIH HHS R01 DA011792NIDA NIH HHS R01 DA039167NIDA NIH HHS R01 DA043204
6 · The paper itself

Abstract

rationaleRecent studies report that fentanyl analogs with relatively low pK

objectivesThe present study compared the inflammatory antinociceptive, respiratory-depressant, and reinforcing effects of fentanyl and two analogs of intermediate (FF3) and low (NFEPP) pK

methodsNociception was produced by administration of Complete Freund's Adjuvant into the hind paw of subjects, and antinociception was measured using an electronic Von Frey test. Respiratory depression was measured using whole-body plethysmography. Reinforcing effects were measured in self-administration using a progressive-ratio schedule of reinforcement. The dose ranges tested for each drug encompassed no effect to maximal effects.

resultsAll compounds produced full effects in all measures but varied in potency. FF3 and fentanyl were equipotent in antinociception and self-administration, but FF3 was less potent than fentanyl in respiratory depression. NFEPP was less potent than fentanyl in every measure. The magnitude of potency difference between antinociception and other effects was greater for FF3 than for NFEPP or fentanyl, indicating that FF3 had the widest margin of safety when relating antinociception to respiratory-depressant and reinforcing effects.

conclusionsLow pK

Indexed as

Analgesics, OpioidFentanylRats, Sprague-DawleyAnimalsDose-Response Relationship, DrugFemaleMalePain MeasurementRatsReinforcement, PsychologyRespiratory InsufficiencySelf AdministrationAnalgesics, OpioidFentanylAntinociceptionFentanylFentanyl analogspKaRespiratory depressionSelf-administration

Identifiers

PMID38754577
PMCPMC11195011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.